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The protein tyrosine phosphatase SHP-2 negatively regulates
ciliary neurotrophic factor induction of gene expression
Aviva Symes*†, Neil Stahl‡, Steven A. Reeves§, Thomas Farruggella‡, Tiziana
Servidei§, Tom Gearan*, George Yancopoulos‡ and J. Stephen Fink*
Ciliary neurotrophic factor, along with other
neuropoietic cytokines, signals through the shared
receptor subunit gp130 [1–3], leading to the tyrosine
phosphorylation of a number of substrates [4,5],
including the transcription factors STAT1 and STAT3
and the protein tyrosine phosphatase SHP-2 [6–8].
SHP-2 (also known as PTP1D, SHPTP2, Syp and
PTP2C) is a positive regulatory molecule required for
the activation of the mitogen-activated protein kinase
pathway and the stimulation of gene expression in
response to epidermal growth factor, insulin and
platelet-derived growth factor stimulation [9–11]. We
have previously shown that cytokines that signal via
the gp130 receptor subunit activate transcription of the
vasoactive intestinal peptide (VIP) gene through a
180 bp cytokine response element (CyRE) [12,13]. To
characterize the role of SHP-2 in the regulation of
gp130-stimulated gene expression, we examined the
regulation of the VIP CyRE in two systems that
prevented ligand-dependent SHP-2 phosphorylation.
Inhibition of SHP-2, either by mutating the tyrosine
residue in gp130 that mediates the SHP-2 interaction,
or by expression of dominant-negative SHP-2, resulted
in dramatic increases in gp130-dependent gene
expression, through the VIP CyRE and more
specifically through multimerized STAT-binding sites.
These data suggest that SHP-2 has a negative role in
gp130 signaling by modulating STAT-mediated
transcriptional activation.
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Results and discussion
The cytoplasmic tail of gp130 contains five tyrosine
residues (Y1–Y5) that can become phosphorylated after
ligand activation of the receptor [6]: the four carboxy-termi-
nal tyrosine residues (Y2–Y5) mediate the phosphorylation
and activation of STAT3 and STAT1 [6] and the more
membrane-proximal Y1 residue mediates the association
and tyrosine phosphorylation of the protein tyrosine
phosphatase SHP-2 [6]. In order to determine the contribu-
tion of the different tyrosine residues in the receptor to
Figure 1
STAT-docking sites on the gp130 cytoplasmic tail
are necessary to direct transcriptional induction
through the VIP CyRE. NBFL cells (7× 105 cells
per 10 cm plate) were transfected by calcium-
phosphate precipitation with a series of chimeric
EGF receptor–gp130 deletion mutants (6µg) [6]
together with Cy1luc (5 µg), which contains the
VIP CyRE upstream of a basal RSV promoter
driving transcription of the luciferase gene [12].
RSVCAT was used as a control for transfection
efficiency. Cells were treated with EGF (5 ng/ml)
12 h after transfection for 36 h before harvesting
and analysis of the resultant luciferase and CAT
activity. The data shown are the results of 3–5
independent experiments and are expressed as a
percentage fold induction of luciferase activity
(mean + s.e.m.), with induction by the wild-type
EGF receptor being 100%. The differences in
luciferase activity between the receptor plasmids
are significant (*p < 0.001).
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gp130-mediated regulation of gene expression, we trans-
fected the NBFL neuroblastoma cell line with a series of
epidermal growth factor (EGF) receptor–gp130 receptor
chimeras composed of the extracellular domain of the
EGF receptor fused to various truncations of the cytoplas-
mic domain of gp130 [6] (Figure 1). We assayed gp130-
activated gene expression using the luciferase reporter
plasmid Cy1luc, which contains the 180 bp cytokine
response element (CyRE) of the vasoactive intestinal
peptide (VIP) promoter. The CyRE is necessary and suffi-
cient to mediate transcriptional activation of the VIP gene
by ciliary neurotrophic factor (CNTF) and leukemia
inhibitory factor (LIF) [12]. 
Sequential deletion of the carboxy-terminal tyrosines of
gp130 gradually reduced EGF-stimulated luciferase activ-
ity from Cy1luc (Figure 1). Deletion of the Y2 residue
abolished the ability of the chimeric receptor to activate
CyRE-mediated transcription (Figure 1). Similar results
were obtained with a series of TrkC–gp130 (TG) chimeric
receptors, which were stimulated by the TrkC-activating
ligand neurotrophin-3 (NT-3; data not shown). Deletion
of the region encompassing the gp130 Y2–Y5 residues
abrogated ligand-induced STAT activation, suggesting
that STAT activation is necessary for the chimeric recep-
tor to activate CyRE-mediated gene transcription. The
gp130 Y1 residue, which mediates phosphorylation of
SHP-2 [6], was not sufficient to mediate transcriptional
induction through the VIP CyRE (Figure 1).
To assess whether SHP-2 contributes to the gp130-medi-
ated activation of CyRE-directed gene expression, we used
TG chimeric receptors that contained point mutations of
the tyrosine residues in the gp130 cytoplasmic tail: in
TGY1F and TGY2F, the Y1 and the Y2 tyrosines, respec-
tively, were mutated to phenylalanine. In NBFL cells,
TGY1F did not mediate ligand-dependent SHP-2 phos-
phorylation or SHP-2 association with the receptor
(Figure 2d), but retained the ability to mediate phosphory-
lation of STAT3 (data not shown). Like the unmutated
TG chimeric receptor, TGY2F could mediate both SHP-2
and STAT3 phosphorylation [6]. Interestingly, in NBFL
cells transfected with the TGY1F receptor, NT-3 induced
a five-fold higher level of luciferase activity than that in
cells expressing the unmutated TG receptor (Figure 2a).
Cy1luc induction was not mediated by endogenous TrkC
receptors because NT-3 did not induce luciferase activity
in the absence of chimeric receptors (data not shown).
NT-3 treatment of cells expressing the mutated TGY2F
receptor induced luciferase activity to a similar level as that
observed for the unmutated TG receptor (Figure 2a). All
three chimeric receptors were phosphorylated on tyrosine
residues in the presence of NT-3, and there was no repro-
ducible difference in either the amount of NT-3-depen-
dent tyrosine phosphorylation or the expression level of the
constructs (Figure 2c,d). These data indicate that phospho-
rylation of the Y1 residue normally downregulates gp130-
stimulated transcription. The Y1 residue of the gp130
receptor is only known to be required for SHP-2 tyrosine
phosphorylation, suggesting that activated SHP-2 limits the
extent of transcriptional stimulation triggered by gp130. 
The VIP CyRE is a complex transcriptional element
composed of different regions that interact with a variety
of transcription factors [12–14]. To assess directly the
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Mutation of the gp130 SHP-2-docking site induces gp130-mediated
transcription and prevents SHP-2 tyrosine phosphorylation and receptor
association. NBFL cells were transfected with a series of Myc-tagged
chimeric TrkC–gp130 receptor plasmids together with either (a) Cy1luc or
(b) 3(G3)luc, including RSVCAT as a control for transfection efficiency.
Cells were treated with NT-3 (20 ng/ml) for 36 h before harvesting and
analysing the resultant luciferase activity. Data are presented as the mean
fold induction of luciferase activity normalized to CAT activity
(n = 3 + s.e.m.). The differences in luciferase activity between the receptor
plasmids are significant (*p < 0.001). (c,d) NBFL cells were transfected with
the chimeric receptors and treated with NT-3 (20 ng/ml) for 10 min and
washed and lysed as described [22]. Total cell lysates were either blotted
with the Myc 9E10 antibody to check for expression of the receptor
chimeras, or first immunoprecipitated with (c) the 9E10 antibody or (d) the
anti-SHP-2 antibody and subsequently immunoblotted with the
antiphosphotyrosine (anti-PY) antibody 4G10 (Transduction Laboratories).
All immunoblots were visualized with enhanced chemiluminescence. The
filled arrows indicate the position of the Myc-tagged chimeric receptors, and
the open arrow indicates the position of tyrosine-phosphorylated SHP-2.
relevance of the Y1F and Y2F mutations on STAT-medi-
ated transcription, NBFL cells were transfected with the
TG receptor chimeras and the luciferase reporter plasmid
3(G3)luc, which contains three copies of the VIP CyRE
STAT-binding site [12,14]. Luciferase activity was
induced 760-fold upon NT-3 stimulation of the TGY1F
receptor (Figure 2b), but only 50-fold by NT-3 stimula-
tion of either the unmutated TG receptor, or the TGY2F
receptor mutant. Thus, mutation of the Y1 residue results
in a dramatic increase in STAT-mediated transcriptional
activation, suggesting that recruitment and activation of
SHP-2 is involved in the downregulation of STAT-medi-
ated transcription. 
NT-3 treatment of NBFL cells transfected with each of
the chimeric receptors led to tyrosine phosphorylation of
STAT3 (data not shown). Increases in STAT-mediated
transcription in cells transfected with the TGY1F receptor
might result from prolonged phosphorylation of this
receptor leading to greater STAT activation over time:
such differences were not detected after 10 minutes of
NT-3 treatment (data not shown). Indeed, the positive
effect of the TGY1F mutation on STAT-driven transcrip-
tion increased with NT-3 treatment up to 36 hours, the
longest time point assayed (data not shown). Thus SHP-2,
activated by binding to phosphotyrosine motifs on gp130,
might dephosphorylate gp130 and/or other proteins impor-
tant for the JAK–STAT pathway.
We used dominant-negative SHP-2 proteins [15] to exam-
ine the effect of inhibiting CNTF-mediated activation of
SHP-2 on induction of the VIP CyRE. These mutant
SHP-2 proteins associate with gp130 in a CNTF-depen-
dent manner (Figure 3c) in a similar way to endogenous
SHP-2 (data not shown). The dominant-negative SHP-2
proteins contain the Src homology 2 (SH2) domains at the
amino terminus of the protein, but lack the phosphatase
domain and carboxy-terminal tyrosine residues [10,15].
Binding of phosphotyrosine residues by the SH2 domains
in wild-type SHP-2 is thought to activate its phosphatase
activity [16]. The modified SHP-2 proteins act in a domi-
nant-negative manner by competing with endogenous
SHP-2 for their ‘docking’ phosphotyrosines on the cyto-
plasmic tail of gp130.
NBFL cells cotransfected with a plasmid encoding the
dominant-negative SHP-2 protein NP2 (which contains
the SHP-2 amino-terminal SH2 domain alone) and the
Cy1luc reporter plasmid had approximately seven-fold
higher levels of CNTF-stimulated luciferase activity than
cells transfected with Cy1luc alone (Figure 3a). This
increase was dose-dependent because increasing amounts
of NP2 increased the CNTF-mediated stimulation of
luciferase activity from Cy1luc (Figure 3b). The effect
was specific to the SH2 domains of SHP-2 because a
plasmid containing either both SH2 domains of the
related phosphatase SHP-1 (NCP1, Figure 3a) or the SHP-
1 amino-terminal SH2 domain alone (data not shown) did
not increase Cy1luc-driven transcription, but instead had a
slight inhibitory effect. These data suggest that SHP-2
downregulates gp130-mediated stimulation of VIP gene
expression and contrast with previous reports of inhibitory
roles for dominant-negative SHP-2 proteins in growth
factor/cytokine stimulation of transcription [9,17,18]. 
Interestingly, the dominant-negative protein NCP2, con-
taining both SHP-2 SH2 domains, increased CNTF-stim-
ulated luciferase activity from Cy1luc to a lesser extent
than NP2 (Figure 3a). Nonetheless, in cells transfected
with a plasmid expressing NCP2, luciferase activity from
Cy1luc was two-fold greater than in cells transfected with
Cy1luc alone. A similar increase was seen in NBFL cells
transfected with a plasmid encoding a different dominant-
negative SHP-2 protein containing an inactivating cys-
teine to serine mutation of the essential catalytic cysteine
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Figure 3
Dominant-negative SHP-2 stimulates CNTF-mediated induction of
transcription through the VIP CyRE. NBFL cells were transfected with
Cy1luc together with (a) 4 µg plasmid expressing dominant-negative SHP
proteins under the control of the cytomegalovirus promoter or (b)
increasing amounts of NP2, the amino-terminal SH2 domain of SHP-2.
NCP2 contains both amino-terminal and carboxy-terminal SH2 domains of
SHP-2, and NCP1 contains both SH2 domains of the related phosphatase,
SHP-1. Transfected cells were stimulated with CNTF (25 ng/ml) for 36 h
before harvesting and analysing the resultant luciferase activity. Data are
expressed relative to the luciferase activity in untreated NBFL cells
transfected with Cy1luc and the control vector RK5. The data shown are
the mean of 2–7 independent experiments each performed in duplicate. 
(c) NBFL cells transfected with plasmids expressing dominant-negative
SHP-2 were stimulated with CNTF (25 ng/ml) for 10 min and washed and
lysed as before. The dominant-negative proteins were tagged with a FLAG
epitope at their carboxyl terminus allowing for detection with an anti-FLAG
antibody (M2; Kodak/IBI). Lysates were immunoprecipitated with the M2
antibody and immunoblotted with an anti-gp130 antibody (Santa Cruz). The
arrow indicates the position of SHP-2-associated gp130.
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in the phosphatase domain of the full-length protein (data
not shown). It is unclear why the SHP-2 amino-terminal
SH2 domain alone induces a greater response than both
SH2 domains. The amino-terminal SH2 domain of SHP-2
can interact with gp130 (Figure 3c). The function of the
carboxy-terminal SH2 domain remains unclear, however:
it might reduce the affinity of the amino-terminal SH2
domain for the gp130 receptor; alternatively, it might int-
eract with a phosphotyrosine residue on a distinct protein
and either regulate a different pathway with opposing
actions to that of SHP-2 or sterically hinder the interaction
of the SHP-2 amino terminus with the gp130 receptor. 
The results from the mutation of the gp130 Y1 residue and
expression of dominant-negative SHP-2 proteins suggest
that the presence and activation of SHP-2 normally down-
regulates gp130-dependent gene expression. Consistent
with these data, expression of dominant-negative SHP-2
in primary sympathetic neurons enhances CNTF-induced
expression of VIP and another neuropeptide, substance P
(T. Servidei and S.A. Reeves, unpublished observations).
Also, a mutation in the related leptin receptor OB-R that
prevents phosphorylation of SHP-2 upregulates leptin-
mediated STAT gene induction (L. Carpenter and N.
Stahl, unpublished observations).
A positive regulatory role in signal transduction has previ-
ously been assigned to SHP-2, linking various ligand-acti-
vated receptors, ranging from the interferon α/β receptor
to the insulin receptor, to the activation of the Ras–MAP
kinase pathway [10,11,18–20]. In addition, the SHP-2-
binding Y1 residue in gp130, which  we found to mediate a
negative regulatory role in NBFL cells, has recently been
shown to link gp130 to the activation of extracellular
signal-regulated kinase 2 (ERK2), through association of
SHP-2 and the adaptor molecule Grb2 in BAF-B03 cells
[21]. This SHP-2-mediated activation of ERK2 is neces-
sary for gp130-mediated mitogenesis. Thus, the finding
that SHP-2 might play a negative role in gp130-regulated
gene expression is surprising and suggests that gp130-acti-
vated SHP-2 may serve two distinct functions. It is not yet
known whether separate domains of SHP-2 are required
to elicit these distinct roles, or whether the different path-
ways diverge further downstream of SHP-2. Our present
data support the idea that SHP-2 is a dual-function tyro-
sine phosphatase that can have positive or negative effects
on gene transcription depending on the cell type or target
of the signaling pathway in which it acts.
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